Literature DB >> 29384150

Multiple sclerosis in 2017: Progress in multiple sclerosis - from diagnosis to therapy.

Maria Trojano1, Maria Pia Amato2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29384150     DOI： 10.1038/nrneurol.2018.3

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  9 in total

Review 1.  The tension between early diagnosis and misdiagnosis of multiple sclerosis.

Authors:  Andrew J Solomon; John R Corboy
Journal:  Nat Rev Neurol       Date:  2017-08-11       Impact factor: 42.937

2.  Overexpression of the Cytokine BAFF and Autoimmunity Risk.

Authors:  Maristella Steri; Valeria Orrù; M Laura Idda; Maristella Pitzalis; Mauro Pala; Ilenia Zara; Carlo Sidore; Valeria Faà; Matteo Floris; Manila Deiana; Isadora Asunis; Eleonora Porcu; Antonella Mulas; Maria G Piras; Monia Lobina; Sandra Lai; Mara Marongiu; Valentina Serra; Michele Marongiu; Gabriella Sole; Fabio Busonero; Andrea Maschio; Roberto Cusano; Gianmauro Cuccuru; Francesca Deidda; Fausto Poddie; Gabriele Farina; Mariano Dei; Francesca Virdis; Stefania Olla; Maria A Satta; Mario Pani; Alessandro Delitala; Eleonora Cocco; Jessica Frau; Giancarlo Coghe; Lorena Lorefice; Giuseppe Fenu; Paola Ferrigno; Maria Ban; Nadia Barizzone; Maurizio Leone; Franca R Guerini; Matteo Piga; Davide Firinu; Ingrid Kockum; Izaura Lima Bomfim; Tomas Olsson; Lars Alfredsson; Ana Suarez; Patricia E Carreira; Maria J Castillo-Palma; Joseph H Marcus; Mauro Congia; Andrea Angius; Maurizio Melis; Antonio Gonzalez; Marta E Alarcón Riquelme; Berta M da Silva; Maurizio Marchini; Maria G Danieli; Stefano Del Giacco; Alessandro Mathieu; Antonello Pani; Stephen B Montgomery; Giulio Rosati; Jan Hillert; Stephen Sawcer; Sandra D'Alfonso; John A Todd; John Novembre; Gonçalo R Abecasis; Michael B Whalen; Maria G Marrosu; Alessandra Meloni; Serena Sanna; Myriam Gorospe; David Schlessinger; Edoardo Fiorillo; Magdalena Zoledziewska; Francesco Cucca
Journal:  N Engl J Med       Date:  2017-04-27       Impact factor: 91.245

3.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Authors:  Xavier Montalban; Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Jérôme de Seze; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Annette Sauter; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Hideki Garren; Nicole Mairon; Peter Chin; Jerry S Wolinsky
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

Review 4.  Clinical outcome measures for progressive MS trials.

Authors:  Daniel Ontaneda; Jeffrey A Cohen; Maria Pia Amato
Journal:  Mult Scler       Date:  2017-10       Impact factor: 6.312

5.  Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.

Authors:  Lenka Novakova; Markus Axelsson; Mohsen Khademi; Henrik Zetterberg; Kaj Blennow; Clas Malmeström; Fredrik Piehl; Tomas Olsson; Jan Lycke
Journal:  J Neurochem       Date:  2016-11-29       Impact factor: 5.372

6.  Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Authors:  Kathleen Hawker; Paul O'Connor; Mark S Freedman; Peter A Calabresi; Jack Antel; Jack Simon; Stephen Hauser; Emmanuelle Waubant; Timothy Vollmer; Hillel Panitch; Jiameng Zhang; Peter Chin; Craig H Smith
Journal:  Ann Neurol       Date:  2009-10       Impact factor: 10.422

7.  Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.

Authors:  Ari J Green; Jeffrey M Gelfand; Bruce A Cree; Carolyn Bevan; W John Boscardin; Feng Mei; Justin Inman; Sam Arnow; Michael Devereux; Aya Abounasr; Hiroko Nobuta; Alyssa Zhu; Matt Friessen; Roy Gerona; Hans Christian von Büdingen; Roland G Henry; Stephen L Hauser; Jonah R Chan
Journal:  Lancet       Date:  2017-10-10       Impact factor: 79.321

Review 8.  MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.

Authors:  Massimo Filippi; Maria A Rocca; Olga Ciccarelli; Nicola De Stefano; Nikos Evangelou; Ludwig Kappos; Alex Rovira; Jaume Sastre-Garriga; Mar Tintorè; Jette L Frederiksen; Claudio Gasperini; Jacqueline Palace; Daniel S Reich; Brenda Banwell; Xavier Montalban; Frederik Barkhof
Journal:  Lancet Neurol       Date:  2016-01-26       Impact factor: 44.182

9.  Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.

Authors:  Giulio Disanto; Christian Barro; Pascal Benkert; Yvonne Naegelin; Sabine Schädelin; Antonella Giardiello; Chiara Zecca; Kaj Blennow; Henrik Zetterberg; David Leppert; Ludwig Kappos; Claudio Gobbi; Jens Kuhle
Journal:  Ann Neurol       Date:  2017-06       Impact factor: 10.422
  9 in total
  2 in total

1.  Nodal Dynamics after In Vivo Rescue of βIV Spectrin Expression.

Authors:  Clara Maria Bacmeister; Michael Andrew Thornton
Journal:  J Neurosci       Date:  2019-01-02       Impact factor: 6.167

2.  Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis.

Authors:  Fernando Cavalcanti; Elena Gonzalez-Rey; Mario Delgado; Clara P Falo; Leyre Mestre; Carmen Guaza; Francisco O'Valle; Michele M P Lufino; Jordi Xaus; Cristina Mascaró; Serena Lunardi; Natalia Sacilotto; Paola Dessanti; David Rotllant; Xavier Navarro; Mireia Herrando-Grabulosa; Carlos Buesa; Tamara Maes
Journal:  Pharmaceutics       Date:  2022-07-06       Impact factor: 6.525
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.